publicationMetadata:
  pmid: "30615146"
  title: "Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development."
  queryType: "bench,clinical"
  publicationType: "Lab Research"
  publicationTypeConfidence: 0.95
  hasMethodsSection: Yes
  likelyContainsTools: Yes
  expectedToolTypes: |
    Lab Research â†’ antibodies, cell lines, animal models, genetic reagents, computational tools, organoids, PDX
    
    This is a preclinical laboratory study investigating MEK inhibitors in schwannoma models. Expected tools include:
    - Cell lines (merlin-deficient Schwann cells, primary human VS cells)
    - Animal models (NF2 transgenic mice, orthotopic allograft models)
    - Computational tools (proteome analysis, DNA methylation analysis)
    - Genetic reagents (MEK1/2 inhibitors as research compounds)
    - Antibodies (for detecting pERK1/2, cyclin D1, p27, Ki-67, caspase-3)
  overallAssessment: |
    This is a comprehensive preclinical laboratory study that extensively uses research tools across multiple categories.
    The study involves cell culture experiments, animal model testing, proteomic analysis, and molecular pathway analysis.
    Multiple research tools should be present including cell lines, animal models, antibodies for protein detection, and computational tools for data analysis.

toolValidations: []

potentiallyMissedTools:
  - toolName: "MD-MSC"
    toolType: "cell_line"
    foundIn: "methods"
    contextSnippet: "Mouse and human merlin-deficient Schwann cell lines (MD-MSC/HSC) were screened against 6 MEK1/2 inhibitors"
    whyMissed: "Cell line abbreviation not recognized by mining patterns"
    confidence: 0.9
    shouldBeAdded: Yes

  - toolName: "MD-HSC"
    toolType: "cell_line"
    foundIn: "methods"
    contextSnippet: "Mouse and human merlin-deficient Schwann cell lines (MD-MSC/HSC) were screened against 6 MEK1/2 inhibitors"
    whyMissed: "Cell line abbreviation not recognized by mining patterns"
    confidence: 0.9
    shouldBeAdded: Yes

  - toolName: "NF2 transgenic mouse model"
    toolType: "animal_model"
    foundIn: "methods"
    contextSnippet: "Efficacious drugs were tested in orthotopic allograft and NF2 transgenic mouse models"
    whyMissed: "Transgenic mouse model phrase not captured by patterns"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "orthotopic allograft model"
    toolType: "animal_model"
    foundIn: "methods"
    contextSnippet: "Efficacious drugs were tested in orthotopic allograft and NF2 transgenic mouse models"
    whyMissed: "Allograft model terminology not recognized"
    confidence: 0.9
    shouldBeAdded: Yes

  - toolName: "primary human VS cells"
    toolType: "cell_line"
    foundIn: "methods"
    contextSnippet: "Drug efficacy was examined in primary human VS cells with NF2 mutations"
    whyMissed: "Primary cell culture terminology not captured"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "trametinib"
    toolType: "genetic_reagent"
    foundIn: "results"
    contextSnippet: "Trametinib, PD0325901, and cobimetinib were most effective in reducing MD-MSC/HSC viability"
    whyMissed: "MEK inhibitor compounds not recognized as research reagents"
    confidence: 0.8
    shouldBeAdded: Yes

  - toolName: "PD0325901"
    toolType: "genetic_reagent"
    foundIn: "results"
    contextSnippet: "Trametinib, PD0325901, and cobimetinib were most effective in reducing MD-MSC/HSC viability"
    whyMissed: "MEK inhibitor compounds not recognized as research reagents"
    confidence: 0.8
    shouldBeAdded: Yes

  - toolName: "cobimetinib"
    toolType: "genetic_reagent"
    foundIn: "results"
    contextSnippet: "Trametinib, PD0325901, and cobimetinib were most effective in reducing MD-MSC/HSC viability"
    whyMissed: "MEK inhibitor compounds not recognized as research reagents"
    confidence: 0.8
    shouldBeAdded: Yes

  - toolName: "pERK1/2 antibody"
    toolType: "antibody"
    foundIn: "results"
    contextSnippet: "Each decreased phosphorylated pERK1/2 and cyclin D1, increased p27"
    whyMissed: "Antibody target mentioned without explicit 'antibody' keyword"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "cyclin D1 antibody"
    toolType: "antibody"
    foundIn: "results"
    contextSnippet: "Each decreased phosphorylated pERK1/2 and cyclin D1, increased p27"
    whyMissed: "Antibody target mentioned without explicit 'antibody' keyword"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "p27 antibody"
    toolType: "antibody"
    foundIn: "results"
    contextSnippet: "Each decreased phosphorylated pERK1/2 and cyclin D1, increased p27"
    whyMissed: "Antibody target mentioned without explicit 'antibody' keyword"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "Ki-67 antibody"
    toolType: "antibody"
    foundIn: "results"
    contextSnippet: "decreased pERK1/2, cyclin D1, and Ki-67 levels were observed only in PD0325901 and cobimetinib-treated grafts"
    whyMissed: "Antibody target mentioned without explicit 'antibody' keyword"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "caspase-3 antibody"
    toolType: "antibody"
    foundIn: "results"
    contextSnippet: "increased p27, and induced caspase-3 cleavage in MD-MSCs"
    whyMissed: "Antibody target mentioned without explicit 'antibody' keyword"
    confidence: 0.85
    shouldBeAdded: Yes

suggestedPatterns:
  - patternType: "naming_convention"
    pattern: "MD-[A-Z]{2,4}"
    toolType: "cell_line"
    examples: ["MD-MSC", "MD-HSC"]
    reasoning: "Merlin-deficient cell line abbreviations follow this pattern and are commonly used in NF research"

  - patternType: "context_phrase"
    pattern: "transgenic mouse model"
    toolType: "animal_model"
    examples: ["NF2 transgenic mouse models"]
    reasoning: "Transgenic mouse models are frequently mentioned but not captured by current patterns"

  - patternType: "context_phrase"
    pattern: "orthotopic allograft"
    toolType: "animal_model"
    examples: ["orthotopic allograft and NF2 transgenic mouse models"]
    reasoning: "Orthotopic allograft models are specialized animal model systems not captured"

  - patternType: "context_phrase"
    pattern: "primary [a-zA-Z]+ cells"
    toolType: "cell_line"
    examples: ["primary human VS cells"]
    reasoning: "Primary cell cultures are important research tools but not consistently captured"

  - patternType: "term"
    pattern: "trametinib|PD0325901|cobimetinib|selumetinib|binimetinib"
    toolType: "genetic_reagent"
    examples: ["trametinib", "PD0325901", "cobimetinib"]
    reasoning: "MEK inhibitor compounds are research reagents but not recognized by current patterns"

  - patternType: "context_phrase"
    pattern: "(decreased|increased|reduced|elevated)\\s+[a-zA-Z0-9/]+\\s+(levels?|expression)"
    toolType: "antibody"
    examples: ["decreased pERK1/2", "increased p27", "Ki-67 levels"]
    reasoning: "Protein level measurements strongly indicate antibody usage for detection"

  - patternType: "context_phrase"
    pattern: "proteomic analysis"
    toolType: "computational_tool"
    examples: ["Proteomic analysis confirmed cell cycle arrest"]
    reasoning: "Proteomic analysis requires specialized computational tools for data processing"

  - patternType: "context_phrase"
    pattern: "DNA methylation analysis"
    toolType: "computational_tool"
    examples: ["DNA methylation analysis of PD0325901-resistant versus -susceptible VS"]
    reasoning: "DNA methylation analysis requires computational tools for data analysis"

observations:
  - resourceName: "trametinib"
    resourceType: "Genetic Reagent"
    observationType: "Cellular"
    observationTypeOntologyId: ""
    details: |
      Trametinib was most effective in reducing MD-MSC/HSC viability. It decreased phosphorylated pERK1/2 and cyclin D1, 
      increased p27, and induced caspase-3 cleavage in MD-MSCs. Proteomic analysis confirmed cell cycle arrest and 
      activation of pro-apoptotic pathways in trametinib-treated MD-MSCs.
    foundIn: "results"
    contextSnippet: "Trametinib, PD0325901, and cobimetinib were most effective in reducing MD-MSC/HSC viability. Each decreased phosphorylated pERK1/2 and cyclin D1, increased p27, and induced caspase-3 cleavage in MD-MSCs. Proteomic analysis confirmed cell cycle arrest and activation of pro-apoptotic pathways in trametinib-treated MD-MSCs."
    confidence: 0.95
    doi: "10.1093/neuonc/noz002"

  - resourceName: "trametinib"
    resourceType: "Genetic Reagent"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      Tumor burden and average tumor size were reduced in trametinib-treated NF2 transgenic mice; however, 
      tumors did not exhibit reduced pERK1/2 levels, suggesting potential resistance mechanisms.
    foundIn: "results"
    contextSnippet: "Tumor burden and average tumor size were reduced in trametinib-treated NF2 transgenic mice; however, tumors did not exhibit reduced pERK1/2 levels."
    confidence: 0.9
    doi: "10.1093/neuonc/noz002"

  - resourceName: "PD0325901"
    resourceType: "Genetic Reagent"
    observationType: "Cellular"
    observationTypeOntologyId: ""
    details: |
      PD0325901 was effective in reducing MD-MSC/HSC viability and showed decreased pERK1/2, cyclin D1, and Ki-67 levels 
      in treated grafts. It modestly reduced viability of several primary human VS cell cultures with NF2 mutations.
    foundIn: "results"
    contextSnippet: "decreased pERK1/2, cyclin D1, and Ki-67 levels were observed only in PD0325901 and cobimetinib-treated grafts. Trametinib and PD0325901 modestly reduced viability of several primary human VS cell cultures with NF2 mutations."
    confidence: 0.9
    doi: "10.1093/neuonc/noz002"

  - resourceName: "cobimetinib"
    resourceType: "Genetic Reagent"
    observationType: "Cellular"
    observationTypeOntologyId: ""
    details: |
      Cobimetinib was effective in reducing MD-MSC/HSC viability and showed decreased pERK1/2, cyclin D1, and Ki-67 levels 
      in treated grafts. The inhibitor slowed allograft growth in animal models.
    foundIn: "results"
    contextSnippet: "decreased pERK1/2, cyclin D1, and Ki-67 levels were observed only in PD0325901 and cobimetinib-treated grafts. The 3 inhibitors slowed allograft growth"
    confidence: 0.9
    doi: "10.1093/neuonc/noz002"

  - resourceName: "NF2 transgenic mouse model"
    resourceType: "Animal Model"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      NF2 transgenic mice showed reduced tumor burden and average tumor size when treated with trametinib, 
      demonstrating the model's utility for testing therapeutic interventions.
    foundIn: "results"
    contextSnippet: "Tumor burden and average tumor size were reduced in trametinib-treated NF2 transgenic mice"
    confidence: 0.9
    doi: "10.1093/neuonc/noz002"

  - resourceName: "MD-MSC"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: ""
    details: |
      MD-MSC (merlin-deficient mouse Schwann cells) showed reduced viability when treated with MEK inhibitors, 
      with decreased pERK1/2 and cyclin D1, increased p27, and induced caspase-3 cleavage.
    foundIn: "results"
    contextSnippet: "Trametinib, PD0325901, and cobimetinib were most effective in reducing MD-MSC/HSC viability. Each decreased phosphorylated pERK1/2 and cyclin D1, increased p27, and induced caspase-3 cleavage in MD-MSCs."
    confidence: 0.9
    doi: "10.1093/neuonc/noz002"

  - resourceName: "primary human VS cells"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: ""
    details: |
      Primary human vestibular schwannoma cells with NF2 mutations showed modest reduction in viability when treated 
      with trametinib and PD0325901, with variability between different cell cultures.
    foundIn: "results"
    contextSnippet: "Trametinib and PD0325901 modestly reduced viability of several primary human VS cell cultures with NF2 mutations."
    confidence: 0.85
    doi: "10.1093/neuonc/noz002"

  - resourceName: "PD0325901"
    resourceType: "Genetic Reagent"
    observationType: "Issue"
    observationTypeOntologyId: ""
    details: |
      DNA methylation analysis revealed differences between PD0325901-resistant versus -susceptible VS cells, 
      identifying genes that could contribute to drug resistance development.
    foundIn: "results"
    contextSnippet: "DNA methylation analysis of PD0325901-resistant versus -susceptible VS identified genes that could contribute to drug resistance."
    confidence: 0.8
    doi: "10.1093/neuonc/noz002"

summary:
  totalToolsMined: 0
  toolsAccepted: 0
  toolsRejected: 0
  toolsUncertain: 0
  potentiallyMissedCount: 13
  newPatternsCount: 8
  observationsExtracted: 8
  observationsByType:
    Cellular: 5
    Tumor Growth: 2
    Issue: 1
  majorIssuesFound: |
    - Complete failure of mining system to detect any tools despite this being a comprehensive preclinical study
    - Multiple cell lines (MD-MSC, MD-HSC, primary human VS cells) completely missed
    - Animal models (NF2 transgenic mice, orthotopic allograft models) not detected
    - Research compounds (MEK inhibitors) not recognized as genetic reagents
    - Antibody targets (pERK1/2, cyclin D1, p27, Ki-67, caspase-3) not captured
    - Computational analysis tools (proteomic analysis, DNA methylation analysis) missed
  recommendations: |
    This publication represents a major failure of the mining system. Despite being a comprehensive preclinical study 
    with extensive tool usage, zero tools were detected. All 13 identified tools should be added to the database.
    
    Key recommendations:
    1. Add all 13 missed tools - they represent genuine research tools with clear experimental usage
    2. Implement the 8 suggested patterns to improve future mining of similar publications
    3. Review mining patterns for cell line abbreviations, animal model terminology, and research compounds
    4. Improve detection of antibody targets mentioned in protein level measurements
    5. Add patterns for computational analysis tools (proteomic, methylation analysis)
    6. Consider this publication as a test case for validating improved mining patterns
    
    The extracted observations provide valuable scientific data about tool efficacy and should be included in the database.
    This case highlights the need for more comprehensive pattern coverage in preclinical research publications.
